Perspective Therapeutics, Inc.

Contributing Author

Recent Articles by Perspective Therapeutics, Inc.

Sep-15	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma CATX GlobeNewswire
Sep-04	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer CATX GlobeNewswire
Sep-03	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors CATX GlobeNewswire
Aug-26	Perspective Therapeutics to Participate in Upcoming September Conferences CATX GlobeNewswire
Aug-13	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results CATX GlobeNewswire
Jul-24	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 CATX GlobeNewswire
Jul-15	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results CATX GlobeNewswire
Jun-21	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial CATX GlobeNewswire
Jun-21	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting CATX GlobeNewswire
May-30	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting CATX GlobeNewswire
May-12	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results CATX GlobeNewswire